Particle.news
Download on the App Store
3 ARTICLES
·
3w ago

FDA Approves VIZZ, First Aceclidine Eye Drop for Age-Related Presbyopia

This once-daily drop employs a pupil-selective pinhole effect to sharpen near focus for up to 10 hours without blurring distance vision.

A new eye drop, approved for us in the United States, promises to help people ditch their reading glasses or contact lenses for up to 10 hours at a time.
Image
These new drops offer up to 10 hours of clearer vision without glasses

Overview

  • VIZZ is the first and only aceclidine-based ophthalmic solution approved by the FDA for treating presbyopia in adults.
  • The drop uses a pupil-selective pinhole effect to sharpen near focus while sparing the eye’s focusing muscles and avoiding side effects tied to pilocarpine-based treatments.
  • Three randomized, double-masked Phase II trials involving hundreds of volunteers and over 30,000 cumulative treatment days found no serious adverse events.
  • Once-daily administration provides up to 10 hours of near-vision relief, reducing dependence on reading glasses, contact lenses, and bifocals.
  • LENZ Therapeutics plans a broad prescription rollout in the U.S. in the fourth quarter of 2025.